Press Releases

Experts voice concerns over pre-judging promising treatments in the pipeline Today, five top Alzheimer’s clinicians and researchers called into question the preliminary proposal from the Centers for Medicare and Medicaid Services (CMS) to limit coverage FDA-approved monoclonal antibodies that target amyloid for the treatment of Alzheimer’s disease. The CMS proposal would alter the course of […]

New survey finds that 83% of neurologists believe that the safety and efficacy of an entire class of drugs should not be determined by the results of one medication. Washington, D.C. (February 2, 2022) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of […]

Washington, D.C. (January 27, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, applauded the announcement today by Biogen Inc. that it would ensure that at least 18 percent of participants in its FDA mandated study will […]

GAP calls for a traditional National Coverage Determination for ADUHELM consistent with past CMS decisions which will ensure access and equity for all patients stricken with Alzheimer’s. Washington, D.C. (January 11, 2022) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for […]

GAP Renews Its Call for CMS to Cover the New Class of Drugs for the Treatment of Alzheimer’s Washington, D.C. (December 20, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, issued the following statement on the […]

iResearch Atlanta will join the Global Alzheimer’s Platform Foundation®’s network (GAP-Net) of clinical trial sites working to bring new treatments to those living with the disease and and improve equity in research. Contact: Peter Buonanno – peterbuonanno@rational360.com – 704.989.5501 WASHINGTON, D.C. (December 7, 2021) – The Global Alzheimer’s Platform Foundation® (GAP) announced that iResearch Atlanta […]

Study leaders at new Global Alzheimer’s Network Site Commit to Improving Equity in Florida Alzheimer’s Research Contact: Peter Buonanno – peterbuonanno@rational360.com – 408-466-5952 Washington, DC (November 18, 2021) – With enrollment in full swing, the Global Alzheimer’s Platform Foundation® (GAP) has announced that K2 Medical Research will join both their GAP-Network of clinical trial sites […]

Washington, DC (November 10, 2021) – The Global Alzheimer’s Platform Foundation® (GAP) welcomes Lynne Hughes, PhD, an international clinical trial research expert, as a Senior Advisor to the organization. Dr. Hughes will further expand GAP’s strength in developing global networks of clinical trial research institutions dedicated to accelerating the discovery of new assessments, treatments, and cures […]

GAP-Net Site, Axiom Clinical Research of Florida, talks about the Bio-Hermes study and what people from traditionally underserved communities can do to get involved in research. We need an accessible means of diagnosing Alzheimer’s disease and research that demonstrates that new therapies and diagnostic tools work for all people. As a neurological researcher and an […]

Contact: Peter Buonanno – peterbuonanno@rational360.com, 704-989-5501 WASHINGTON, D.C. (July 28, 2021) — Today, the Global Alzheimer’s Platform Foundation® (GAP) announced that Gates Ventures and the Alzheimer’s Disease Data Initiative (ADDI) will join the list of biopharma, technology, and nonprofit partners who are contributing to GAP’s breakthrough Alzheimer’s study, Bio-Hermes. Bio-Hermes is the first-ever platform study […]

Patients and Doctors Deserve the Ability to Consider Whether Aducanumab Will Deliver the Best Medical Outcome and Quality of Life Washington, DC (June 7, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation (GAP), a patient-centric organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, issued the following statement on […]

Lilly, AbbVie, Merck, the Alzheimer’s Drug Discovery Foundation, and leading technology companies join the first platform study assessing various biomarker tests’ ability to predict the presence of Alzheimer’s Contact: Pamela Larkin – pamelalarkin@rational360.com, 408-466-5952 Washington, DC (April 20, 2021) – Today, the Global Alzheimer’s Platform Foundation® (GAP) announced eleven biopharma, technology, and nonprofit partners who […]

GAP-Net site Inland Northwest Research LLC screened the first patient in the Roche PADOVA study for an investigational Parkinson’s disease drug. Spokane, Washington (April 12, 2021) – Inland Northwest Research, LLC screened the first patient worldwide for the Parkinson’s Disease PADOVA study. The Global Alzheimer’s Platform Foundation® (GAP) is helping study sponsor Roche (SIX: ROG) […]

GAP President John Dwyer wrote to the FDA in support of the Aducanumab drug developed by Biogen. Dear Dr. Woodcock, On behalf of the Global Alzheimer’s Platform Foundation (GAP) and millions of Alzheimer’s patients and caregivers across the nation, I urge the Food and Drug Administration (FDA) to approve aducanumab for treatment of early stage […]

TRAILBLAZER-ALZ 2 is the second study of donanemab, which showed favorable results in an earlier trial. Washington, DC (March 13, 2021) – Eli Lilly and Company, a leader in Alzheimer’s research for over 30 years, is partnering with the Global Alzheimer’s Platform Foundation® (GAP) to accelerate recruitment services and expand the number of clinical research […]

Statement by GAP President John Dwyer on the results of the Phase 2 trial for Donanemab: We congratulate Eli Lilly on the results of the Donanemab clinical trial showing it significantly slowed the cognitive and functional decline of people with mild Alzheimer’s. This is a major step towards discovery of a disease modifying therapy. Alzheimer’s […]

Statement by Global Alzheimer’s Platform Foundation (GAP) President John Dwyer on today’s announcement that Biogen and Apple are partnering on an observational study to investigate the role Apple Watch and iPhone could play in screening for mild cognitive impairment (MCI):  Today’s announcement by Biogen and Apple marks a significant step on the path to early […]

Global Alzheimer’s Platform Foundation® Chief Science Officer Dr. Richard Mohs testifies at Senate hearing about the Alzheimer’s crisis. Watch the full hearing at United States Senate Committee on Finance. Washington, DC (December 16, 2020) – Today, the Chief Science Officer of the Global Alzheimer’s Platform Foundation® (GAP), Dr. Richard Mohs, testified before the Senate Committee on Finance, […]

Washington, DC (November 25, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding the Alzheimer’s Disease Data Initiative’s (ADDI) launch of the new Alzheimer’s disease data platform, AD Workbench. “Congratulations on the launch of AD Workbench, by our colleagues at the Alzheimer’s Disease Data Initiative (ADDI). The publicly […]

GAP President John Dwyer says aducanumab offers disease-modifying benefit significantly exceeding current therapies Contact: Pamela Larkin, 408-466-5952, pamelalarkin@rational360.com Washington, DC (November 6, 2020) – Today, the President of the Global Alzheimer’s Platform Foundation® (GAP), John Dwyer, testified before the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee regarding Biogen’s breakthrough Alzheimer’s drug aducanumab. Given that clinical […]

Contact: Pamela Larkin, 408-466-5952, pamelalarkin@rational360.com Washington, DC (October 29, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding C2N Diagnostics’ release of the PrecivityADTM blood test. “Congratulations to the C2N Diagnostics team for successfully developing the first blood test of its kind for Alzheimer’s disease. It will transform […]

The Global Alzheimer’s Platform Foundation® Recognizes Rep. Matt Willhite (D-86) with the 2020 National Citizen Scientist Collaborator Award® Contact: Pamela Larkin – pamelalarkin@rational360.com, 408-466-5952 Contact: Belinda Russel – brussell@jemri.net, 561-968-2933 West Palm Beach, FL (October 22, 2020) – The Global Alzheimer’s Platform Foundation® (GAP) has recognized State Representative Matt Willhite (D-86) as the honoree of […]

The Global Alzheimer’s Platform Foundation® Recognizes Deborah Whelan with the 2020 National Citizen Scientist Champion Award® Contact: Pamela Larkin – pamelalarkin@rational360.com, 408-466-5952 Contact: Robert Briggs – robert.briggs@rsfh.com, 267-879-1762 Charleston, SC (October 22, 2020) – The Global Alzheimer’s Platform Foundation® (GAP) has recognized Deborah Whelan, a retiree living with Alzheimer’s disease, as the recipient of the National Citizen Scientist Champion Award®. […]

The Global Alzheimer’s Platform Foundation® Has Recognized Dennis Chan for the 2020 National Citizen Scientist Catalyst Award® Contact: Pamela Larkin – pamelalarkin@rational360.com, 408-466-5952 Boston, MA (October 22, 2020) – The Global Alzheimer’s Platform Foundation® (GAP) has recognized Westford retiree Dennis Chan as the honoree of the National Citizen Scientist Catalyst Award®. The Center for Alzheimer […]